Monday, May 23, 2016 6:30:12 PM
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC) http://abstracts.asco.org/176/AbstView_176_170710.html
Also CB-839 is going to be used in combo with Nivolumab in patients with clear cell renal cell carcinoma, melanoma and non-small cell lung cancer https://clinicaltrials.gov/ct2/show/NCT02771626?term=CB-839&rank=4
Recent CALA News
- Calithera Biosciences Announces Update on Complete Liquidation and Dissolution • GlobeNewswire Inc. • 06/29/2023 08:01:07 PM
- Calithera Biosciences Announces Update on Complete Liquidation and Dissolution • GlobeNewswire Inc. • 05/19/2023 08:01:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM